Moody’s Investor Services upgrades Teva to Ba1

Teva (TEVA) Pharmaceuticals “announced that Moody’s Investor Services has raised the company’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody’s report cites the Company’s strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities.”